Legend Biotech (LEGN) Receivables - Net (2019 - 2026)

Legend Biotech (LEGN) has reported Receivables - Net for 8 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net rose 360.7% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 360.7% YoY) and the FY2025 annual result came in at $13.1 million, up 104.69% from the prior year.
• Receivables - Net retreated to $1.7 million in Q1 2026 per LEGN's latest filing, from $13.1 million in the prior quarter.
• Over the last five years, Receivables - Net for LEGN reached as high as $100.0 million in Q4 2023 and fell as low as $20000.0 in Q3 2023.
• A 5-year average of $15.5 million and a median of $3.3 million in 2024 frame the typical range for Receivables - Net.
• The largest YoY upside for Receivables - Net was 111056.67% in 2023 against a maximum downside of 99.89% in 2023.
• Year by year, Receivables - Net stood at $90000.0 in 2022, then surged by 111056.67% to $100.0 million in 2023, then sank by 93.6% to $6.4 million in 2024, then soared by 104.69% to $13.1 million in 2025, then tumbled by 87.02% to $1.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $1.7 million, $13.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.